»
Anti-Viral Agents
 
 

Anti-Viral Agents, 1st Edition

 
Anti-Viral Agents, 1st Edition,Erik De Clercq,ISBN9780124058804
 
 
 

Advances in Pharmacology

E De Clercq   

Academic Press

9780124058804

9780124055377

384

229 X 152

This new volume of Advances in Pharmacology explores antiviral agents. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Print Book + eBook

USD 307.20
USD 512.00

Buy both together and save 40%

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 256.00

eBook
eBook Overview

VST (VitalSource Bookshelf) format

DRM-free included formats : EPUB, Mobi (for Kindle), PDF, EPUB, Mobi (for Kindle)

USD 256.00
Add to Cart
 
 

Key Features

  • Explores the current state of anti-viral agents
  • Chapters cover a variety of topics such as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV
  • With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike

Description

This new volume of Advances in Pharmacology explores the current state of antiviral agents. Chapters cover such topics as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Readership

Pharmacologists, immunologists, and biochemists

Information about this author is currently not available.

Anti-Viral Agents, 1st Edition

Preface

References

Contributors

Chapter One. Antiviral Agents for Herpes Simplex Virus

Abbreviations

1 Introduction

2 Historical Overview: Therapies for HSV Infections

3 Clinical Experience with ACV, VACV, and FCV Through Two Decades

4 Antiviral Drug Resistance

5 Novel Approaches to HSV Chemotherapy

6 Prospects for Novel Antiviral Compounds and Vaccines

7 Conclusion

Conflict of Interest

References

Further Reading

Chapter Two. Nucleotide Prodrugs for the Treatment of HCV Infection

Abbreviations

1 Introduction

2 Nucleoside Inhibitors

3 Nucleotide Prodrugs

4 Conclusion

Conflict of Interest

References

Chapter Three. HIV Integrase Inhibitors: 20-Year Landmark and Challenges

Abbreviations

1 Introduction

2 Requirement of IN for HIV Replication

3 IN Structure

4 The INSTIs

5 Challenges

6 Conclusion

Conflict of Interest

References

Chapter Four. Advances in the Treatment of Varicella-Zoster Virus Infections

Abbreviations

1 Introduction

2 Vaccination Strategies and Postexposure Prophylaxis

3 Existing Antiviral Treatments

4 Medical Need for New Anti-VZV Agents

5 Development of Novel Anti-VZV Agents

6 Candidate Anti-VZV Drugs

7 Perspectives

8 Conclusion

Conflict of Interest

Acknowledgments

References

Chapter Five. Hepatitis C Virus: Standard-of-Care Treatment

Abbreviations

1 Introduction

2 Curing HCV Infection

3 Interferons

4 Ribavirin

5 Direct HCV Inhibitors (DAAs and HTAs)

6 Interferon-Based Strategies in 2013

7 Interferon-Free Regimens in 2014 and Onward

8 Conclusion

Conflict of Interest

References

Chapter Six. Influenza Virus Resistance to Antiviral Therapy

Abbreviations

1 Introduction

2 Antiviral Drugs Under Development

3 Resistance to Antiviral Therapy

4 Mechanisms of Resistance to NAIs

5 Permissive and Compensatory Mechanisms Governing Primary Resistance

6 Effectiveness of NAIs

7 Conclusion

Conflict of Interest

References

Further Reading

Chapter Seven. The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

Abbreviations

1 Introduction

2 A Flashback from the Discovery of HBV to the Recognition of the Wide Spectrum of Chronic HBV Infection

3 Development of Chronic HBV Infection and the Phases in Its Natural Course

4 Complicating and Associated Conditions and Comorbidities

5 Treatment of CHB

6 Future Treatments for CHB

7 Conclusion

Conflict of Interest

References

Chapter Eight. The Holý Trinity: The Acyclic Nucleoside Phosphonates

Abbreviations

1 Introduction

2 HPMPA

3 Cidofovir

4 Adefovir

5 Tenofovir

6 Tenofovir Combinations

7 Tenofovir for the Prevention of HIV Infections

8 Tenofovir for the Treatment of HBV Infections

9 Tenofovir for PMTCT

10 Tenofovir Toxicity

11 GS-7340, GS-9131, GS-9191, GS-9219

12 Conclusion

Conflict of Interest

Acknowledgments

References

Chapter Nine. The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)

Abbreviations

1 Introduction

2 Reverse Transcriptase

3 Nucleoside Reverse Transcriptase Inhibitors

4 Nonnucleoside Reverse Transcriptase Inhibitors

5 Protease Inhibitors

6 Drug Combinations

7 Clinical Aspects

8 Preexposure Prophylaxis

9 Prevention of Mother-to-Child Transmission

10 Children

11 Toxicity

12 Adherence (Compliance)

13 Resistance

14 New NRTIs, NNRTIs, and PIs

15 Conclusion

Conflict of Interest

Acknowledgments

References

Index

 
 
Free Shipping
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us